Evidence map›Paper›PMID 39373821›Full record

SynthesisHeart failure reviews2025

BNP and NT-proBNP as prognostic biomarkers for the prediction of adverse outcomes in HFpEF patients: A systematic review and meta-analysis.

Lama A Ammar, Gaelle P Massoud, Charbel Chidiac, George W Booz, Raffaele Altara, Fouad A Zouein

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Heart failure reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Biomarkers in Heart Failure: A Review and a Wish.International journal of molecular sciences · 2025
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lama A Ammar *Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut Medical Center, Riad El-Solh, 1107 2020, Beirut, Lebanon.
Gaelle P Massoud *Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut Medical Center, Riad El-Solh, 1107 2020, Beirut, Lebanon.
Charbel ChidiacDivision of Pediatric Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
George W BoozDepartment Pharmacology and Toxicology, School of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
Raffaele Altara *Department of Anatomy & Embryology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Minderbroedersberg 4-6, Maastricht, 6211 LK, The Netherlands. raffaele.altara@maastrichtuniversity.nl.
Fouad A Zouein *Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut Medical Center, Riad El-Solh, 1107 2020, Beirut, Lebanon. fz15@aub.edu.lb.

Funding

Role of obesity in preeclamptic pregnancy.P20GM121334 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI Ashley C. Johnson, Babbette LaMarca · 2017 to 2026
$26.4M
Faculty of Medicine, American University of Beirut Scholarly Concentration Track FundsNIGMS NIH HHS P20 GM121334NIGMS NIH HHS P20GM121334University Research Board, American University of Beirut URB - 103949; URB - 104262; URB - 104115; URB - 104524
6 · The paper itself

Abstract

Heart failure with preserved ejection fraction (HFpEF) presents a challenge in clinical practice due to its complexity and impact on morbidity and mortality. The aim of this systematic review and meta-analysis (SR/MA) was to evaluate the value of B-Type Natriuretic Peptide (BNP) and NT-proBNP in predicting overall adverse outcomes, cardiovascular events, and mortality, in patients with HFpEF. This SR/MA included observational studies and randomized controlled trials (RCTs) that reported the use of BNP and NT-proBNP as prognostic biomarkers for adverse outcomes in HFpEF patients. A comprehensive literature search was conducted using PubMed, EMBASE, and Google, without language restrictions, from inception until June 2024. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. The quality and risk of bias of the included studies were assessed using the Newcastle-Ottawa Scale (NOS). Twenty-two studies involving 10,158 HFpEF patients were included. The analysis showed that BNP is a significant predictor of overall adverse events in HFpEF patients, with an overall HR of 1.34 (95% CI: 1.20-1.52). Similarly, BNP was a significant predictor of cardiovascular events and mortality in HFpEF patients with a HR of 1.36 (95% CI 1.12-1.64) and HR of 1.44 (95% CI: 1.04-1.84), respectively. When analyzing data for NT-proBNP predictive potential, 3 studies confirmed that NT-proBNP is a significant independent prognostic indicator for adverse events, with an overall HR of 1.80 (95% CI: 1.38-2.35). Comparable results were seen for mortality, with higher NT-proBNP levels associated with increased mortality risk and the MA showing a HR of 1.65 (95% CI: 1.55-1.76). This systematic review highlights the valuable prognostic role of BNP and NT-proBNP in predicting overall adverse outcome, cardiovascular events, and mortality in HFpEF patients. Our findings underscore the importance of further research to establish standardized thresholds and investigate BNP and NT-proBNP's potential in predicting morbidity and mortality.

Indexed as

BiomarkersHeart FailureNatriuretic Peptide, BrainPeptide FragmentsStroke VolumeHumansPrognosisBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Adverse eventsCardiovascular eventsDiagnosisHeart failure with preserved ejection fractionMorbidityMortalityNatriuretic peptides

Identifiers

PMID39373821
PMCPMC12002167

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.